サンプル依頼リスト カート
  • English
  • Korean
表紙：重症急性呼吸器症候群治療の世界市場レポート 2024年
市場調査レポート
商品コード
1415774

重症急性呼吸器症候群治療の世界市場レポート 2024年

Severe Acute Respiratory-Syndrome Treatment Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
重症急性呼吸器症候群治療の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

重症急性呼吸器症候群治療の市場規模は近年急速に拡大しています。2023年の29億9,000万米ドルから2024年には34億5,000万米ドルへとCAGR15.3％で拡大します。実績期間の成長は、世界のアウトブレイク対応、抗ウイルス薬開発、ワクチン開発、公衆衛生対策に起因しています。

重症急性呼吸器症候群治療市場規模は、今後数年で急成長が見込まれます。2028年には年間平均成長率（CAGR）15.4％で61億2,000万米ドルに成長します。予測期間の成長は、広域抗ウイルス薬、新たな治療薬、ワクチンの進歩、パンデミック対策に起因しています。予測期間の主な動向には、RNA標的治療薬、AI創薬、国際共同研究、公衆衛生教育などがあります。

呼吸器疾患の有病率の増加は、当面、重症急性呼吸器症候群治療市場の成長の原動力になると予測されます。呼吸器疾患は、呼吸や外部環境とのガス交換などの機能を担う呼吸器系に影響を及ぼすさまざまな病状を包含します。呼吸器疾患において、重症急性呼吸器症候群治療薬は、症状の緩和、呼吸不全の予防、炎症の緩和、最適な酸素濃度の維持に役立っています。例えば、オーストラリアに本部を置く国家機関であるオーストラリア保健福祉研究所の最近のデータでは、オーストラリアにおける呼吸器疾患関連の死亡者数が2020年の43,031人から2021年には46,551人へと顕著に増加することが明らかになっています。このように、呼吸器疾患の発生率の増加が、重症急性呼吸器症候群治療市場の拡大を推進する原動力となっています。

研究開発への投資の急増は、近い将来、重症急性呼吸器症候群治療市場の成長の起爆剤となると思われます。研究開発投資は、しばしばR&Dと略され、新鮮な知識の発掘を目的とした体系的かつ革新的な調査とイニシアチブを実施することを目的とした、組織、政府、または団体による財源と人的専門知識の割り当てに関係します。研究開発投資の強化は、SARSやCOVID-19のような疾患を含む重症急性呼吸器症候群の治療法を進歩させる上で極めて重要な役割を担っています。このような投資は、効果的な医薬品、ワクチン、診断ツール、治療戦略の策定に貢献し、最終的には患者の転帰を改善し、世界ヘルスへの備えを強化します。注目すべきは、2023年8月、米国連邦政府の行政府である米国保健社会福祉省（Department of Health and Human Services：HHS）が、戦略的準備・対応局（Administration for Strategic Preparedness and Response：ASPR）と共同で、プロジェクト・ネクストジェン（Project NextGen）に14億米ドル以上を割り当てたことを明らかにしたことです。このイニシアチブは、次世代のCOVID-19ワクチンと治療法の開発を支援することを目的としています。その結果、研究開発への投資の増加が重症急性呼吸器症候群治療市場の成長の極めて重要な原動力となっています。

北米は、2023年の重症急性呼吸器症候群治療市場において最大の地域でした。西欧は予測期間で最も急成長する地域と予想されます。重症急性呼吸器症候群治療レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の重症急性呼吸器症候群治療市場、薬剤クラス別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 抗生物質
  • 抗ウィルス薬
  • コルチコステロイド
  • モノクローナル抗体
  • その他の薬剤クラス
  • 世界の重症急性呼吸器症候群治療市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 経口
  • 静脈内
  • 世界の重症急性呼吸器症候群治療市場、適応症別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 重症急性呼吸器症候群コロナウイルス（SARS-CoV）
  • 重症急性呼吸器症候群コロナウイルス 2（SARS-CoV-2）
  • 世界の重症急性呼吸器症候群治療市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • 小売薬局
  • その他の流通チャネル

第7章 地域および国の分析

  • 世界の重症急性呼吸器症候群治療市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の重症急性呼吸器症候群治療市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 重症急性呼吸器症候群治療市場の競合情勢
  • 重症急性呼吸器症候群治療市場の企業プロファイル
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd.
    • AbbVie Inc.
    • Merck And Co Inc.
    • Novartis AG

第31章 その他の主要および革新的な企業

  • Bristol Myers Squib company
  • GlaxoSmithKline plc
  • AstraZeneca plc
  • Sanofi SA
  • Eli Lilly And Company
  • Gilead Sciences Inc.
  • Amgen Inc.
  • Johnson And Johnson Private Limited
  • Moderna Inc.
  • Regeneron Pharmaceuticals Inc.
  • Hetero labs Ltd.
  • Alexion Pharmaceuticals Inc.
  • Cadila healthcare Ltd.
  • Genentech Inc.
  • Cipla Ltd.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r12373

“Severe Acute Respiratory-Syndrome Treatment Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on severe acute respiratory-syndrome treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for severe acute respiratory-syndrome treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The severe acute respiratory-syndrome treatment market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Drug Class: Antibiotics; Antiviral; Corticosteroids; Monoclonal Antibodies; Other Drug Classes
  • 2) By Route Of Administration: Oral; Intravenous
  • 3) By Indication: Severe Acute Respiratory Syndrome COVID-19 (SARS-CoV); Severe Acute Respiratory Syndrome COVID-19 2 (SARS-CoV-2)
  • 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Merck And Co Inc.; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Severe acute respiratory syndrome (SARS) is a severe type of pneumonia caused by an airborne virus that can be transmitted through tiny droplets of saliva. This previously unidentified virus belongs to the Coronaviridae family and is known as SARS-associated COVID-19 (SARS-CoV). The treatment for severe acute respiratory syndrome (SARS) involves medical interventions and supportive measures aimed at managing the symptoms and complications of this viral respiratory illness.

The primary classes of drugs used in the treatment of severe acute respiratory syndrome include antibiotics, antivirals, corticosteroids, monoclonal antibodies, and others. Antibiotics are a class of medications used to treat bacterial infections. They function by either killing bacteria or inhibiting their growth, depending on the specific type of antibiotic. In the context of severe acute respiratory syndrome caused by SARS-CoV and SARS-CoV-2, these antibiotics are administered orally and intravenously. They are distributed through various channels, including hospital pharmacies and retail pharmacies, among others.

The severe acute respiratory syndrome treatment market research report is one of a series of new reports from The Business Research Company that provides severe acute respiratory-syndrome treatment market statistics, including severe acute respiratory-syndrome treatment industry global market size, regional shares, competitors with a severe acute respiratory syndrome treatment market share, detailed severe acute respiratory-syndrome treatment market segments, market trends and opportunities and any further data you may need to thrive in the severe acute respiratory-syndrome treatment industry. This severe acute respiratory-syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The severe acute respiratory-syndrome treatment market size has grown rapidly in recent years. It will grow from $2.99 billion in 2023 to $3.45 billion in 2024 at a compound annual growth rate (CAGR) of 15.3%. The growth in the historic period can be attributed to global outbreak response, antiviral drug development, vaccine development, public health preparedness.

The severe acute respiratory-syndrome treatment market size is expected to see rapid growth in the next few years. It will grow to $6.12 billion in 2028 at a compound annual growth rate (CAGR) of 15.4%. The growth in the forecast period can be attributed to broad-spectrum antivirals, emerging therapeutics, vaccine advancements, pandemic preparedness. Major trends in the forecast period include rna-targeted therapies, ai in drug discovery, global collaborations, public health education.

The increasing prevalence of respiratory diseases is anticipated to be a driving force behind the growth of the severe acute respiratory syndrome treatment market in the foreseeable future. Respiratory diseases encompass a spectrum of medical conditions that affect the respiratory system, responsible for functions such as breathing and gas exchange with the external environment. In the context of respiratory diseases, severe acute respiratory syndrome treatments are instrumental in alleviating symptoms, preventing respiratory failure, mitigating inflammation, and sustaining optimal oxygen levels. For instance, recent data from the Australian Institute of Health and Welfare, a national agency based in Australia, revealed a notable upsurge in respiratory disease-related deaths, rising from 43,031 in 2020 to 46,551 in 2021 in Australia. Thus, the increasing incidence of respiratory diseases is the driving force propelling the expansion of the severe acute respiratory syndrome treatment market.

The progressive surge in investments in research and development is poised to be a catalyst for the growth of the severe acute respiratory syndrome treatment market in the near future. These investments in research and development, often abbreviated as R&D, pertain to the allocation of financial resources and human expertise by organizations, governments, or entities with the aim of conducting systematic and innovative investigations and initiatives, with the goal of unearthing fresh knowledge. Augmented R&D investments play a pivotal role in advancing the array of available treatment options for severe acute respiratory syndromes, including conditions like SARS and COVID-19. Such investments contribute to the formulation of effective drugs, vaccines, diagnostic tools, and therapeutic strategies, ultimately enhancing patient outcomes and reinforcing global health preparedness. Notably, in August 2023, the United States Department of Health and Human Services, the executive branch department of the U.S. federal government, disclosed that the U.S. Department of Health and Human Services (HHS), in collaboration with the Administration for Strategic Preparedness and Response (ASPR), had allocated over $1.4 billion for Project NextGen. This initiative aims to support the development of the next generation of COVID-19 vaccines and treatments. Consequently, the increasing investments in research and development are the pivotal driving force behind the growth of the severe acute respiratory syndrome treatment market.

The growth of the severe acute respiratory syndrome treatment market during the forecast period is hampered by the presence of limited treatment options. The constraints of limited treatment options for severe acute respiratory syndrome can lead to challenges in effectively managing patients, resulting in delayed recovery, increased mortality rates, heightened strain on healthcare systems, and significant economic and global health repercussions. For example, as of October 2021, despite extensive global efforts, an effective treatment for severe acute respiratory syndrome (SARS) had not yet been identified, as reported by the Mayo Foundation for Medical Education and Research (MFMER), a non-profit organization. Traditional antibiotics are ineffective against viral infections, and the effectiveness of antiviral drugs in addressing this condition has remained restricted. Consequently, the restricted treatment options pose a hindrance to the growth of the severe acute respiratory syndrome treatment market.

Leading companies actively participating in the severe acute respiratory syndrome treatment market are at the forefront of introducing innovative techniques, with a notable example being multiplexed real-time PCR. Multiplexed real-time PCR is a molecular biology technology that facilitates the simultaneous amplification and detection of multiple DNA or RNA targets in a single procedure. A case in point is the product launched by TransGen Biotech Co. Ltd., a Beijing-based manufacturer and researcher of molecular and cellular biology products, in July 2022. They introduced the Trans-SARS-CoV-2, Influenza A and B, and Respiratory Syncytial Virus Assay. This groundbreaking assay is designed as a multiplexed real-time PCR (polymerase chain reaction) assay, capable of detecting and distinguishing severe acute respiratory syndrome COVID-19 2 (SARS-CoV-2), Influenza A, Influenza B, and respiratory syncytial virus (RSV) in a single specimen. This innovative tool plays a crucial role in the diagnosis and treatment of severe acute respiratory syndromes, including COVID-19, influenza, and RSV, thus aiding in guiding treatment decisions and preventing the spread of these diseases.

In March 2022, AbbVie Inc., a U.S.-based pharmaceutical company, established a collaboration with Scripps Research, an independent, non-profit biomedical research and drug discovery institute also based in the United States. This strategic partnership is geared toward the development of cutting-edge direct-acting antiviral therapies designed for the treatment of COVID-19. The collaboration aims to pioneer innovative solutions for combatting the virus.

Major players in the severe acute respiratory-syndrome treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck And Co Inc., Novartis AG, Bristol Myers Squib company, GlaxoSmithKline plc, AstraZeneca plc, Sanofi SA, Eli Lilly And Company, Gilead Sciences Inc., Amgen Inc., Johnson And Johnson Private Limited, Moderna Inc., Regeneron Pharmaceuticals Inc., Hetero labs Ltd., Alexion Pharmaceuticals Inc., Cadila healthcare Ltd., Genentech Inc., Cipla Ltd., Biogen Inc., Vir Biotechnology Inc., Swedish Orphan Biovitrum AB, Dynavax Technologies Corporation, ViiV Healthcare Limited, Panacea Biotec Limited, CureVac N.V., CN Bio Innovations Ltd., Inovio Pharmaceuticals Inc., Chimerix Inc.

North America was the largest region in the severe acute respiratory syndrome treatment market in 2023. Western Europe is expected to be the fastest-growing region in the forecast period. The regions covered in severe acute respiratory syndrome treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the severe acute respiratory syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The severe acute respiratory syndrome treatment market consists of revenues earned by entities by providing services such as respiratory therapy, oxygen therapy, ventilation, intensive care, isolation and infection control, fluid and electrolyte management and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The severe acute respiratory syndrome treatment market also includes sales of azithromycin, immunomodulators, vaccines, ribavirin, ritonavir, remdesivir, methylprednisolone, prednisolone, dexamethasone and interferon. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Severe Acute Respiratory-Syndrome Treatment Market Characteristics

3. Severe Acute Respiratory-Syndrome Treatment Market Trends And Strategies

4. Severe Acute Respiratory-Syndrome Treatment Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Severe Acute Respiratory-Syndrome Treatment Market Size and Growth

  • 5.1. Global Severe Acute Respiratory-Syndrome Treatment Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Severe Acute Respiratory-Syndrome Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Severe Acute Respiratory-Syndrome Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Severe Acute Respiratory-Syndrome Treatment Market Segmentation

  • 6.1. Global Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Antibiotics
  • Antiviral
  • Corticosteroids
  • Monoclonal Antibodies
  • Other Drug Classes
  • 6.2. Global Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Route Of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Intravenous
  • 6.3. Global Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
  • Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
  • 6.4. Global Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Other Distribution Channels

7. Severe Acute Respiratory-Syndrome Treatment Market Regional And Country Analysis

  • 7.1. Global Severe Acute Respiratory-Syndrome Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Severe Acute Respiratory-Syndrome Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Severe Acute Respiratory-Syndrome Treatment Market

  • 8.1. Asia-Pacific Severe Acute Respiratory-Syndrome Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Severe Acute Respiratory-Syndrome Treatment Market

  • 9.1. China Severe Acute Respiratory-Syndrome Treatment Market Overview
  • 9.2. China Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Severe Acute Respiratory-Syndrome Treatment Market

  • 10.1. India Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Severe Acute Respiratory-Syndrome Treatment Market

  • 11.1. Japan Severe Acute Respiratory-Syndrome Treatment Market Overview
  • 11.2. Japan Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Severe Acute Respiratory-Syndrome Treatment Market

  • 12.1. Australia Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Severe Acute Respiratory-Syndrome Treatment Market

  • 13.1. Indonesia Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Severe Acute Respiratory-Syndrome Treatment Market

  • 14.1. South Korea Severe Acute Respiratory-Syndrome Treatment Market Overview
  • 14.2. South Korea Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Severe Acute Respiratory-Syndrome Treatment Market

  • 15.1. Western Europe Severe Acute Respiratory-Syndrome Treatment Market Overview
  • 15.2. Western Europe Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Severe Acute Respiratory-Syndrome Treatment Market

  • 16.1. UK Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Severe Acute Respiratory-Syndrome Treatment Market

  • 17.1. Germany Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Severe Acute Respiratory-Syndrome Treatment Market

  • 18.1. France Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Severe Acute Respiratory-Syndrome Treatment Market

  • 19.1. Italy Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Severe Acute Respiratory-Syndrome Treatment Market

  • 20.1. Spain Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Severe Acute Respiratory-Syndrome Treatment Market

  • 21.1. Eastern Europe Severe Acute Respiratory-Syndrome Treatment Market Overview
  • 21.2. Eastern Europe Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Severe Acute Respiratory-Syndrome Treatment Market

  • 22.1. Russia Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Severe Acute Respiratory-Syndrome Treatment Market

  • 23.1. North America Severe Acute Respiratory-Syndrome Treatment Market Overview
  • 23.2. North America Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Severe Acute Respiratory-Syndrome Treatment Market

  • 24.1. USA Severe Acute Respiratory-Syndrome Treatment Market Overview
  • 24.2. USA Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Severe Acute Respiratory-Syndrome Treatment Market

  • 25.1. Canada Severe Acute Respiratory-Syndrome Treatment Market Overview
  • 25.2. Canada Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Severe Acute Respiratory-Syndrome Treatment Market

  • 26.1. South America Severe Acute Respiratory-Syndrome Treatment Market Overview
  • 26.2. South America Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Severe Acute Respiratory-Syndrome Treatment Market

  • 27.1. Brazil Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Severe Acute Respiratory-Syndrome Treatment Market

  • 28.1. Middle East Severe Acute Respiratory-Syndrome Treatment Market Overview
  • 28.2. Middle East Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Severe Acute Respiratory-Syndrome Treatment Market

  • 29.1. Africa Severe Acute Respiratory-Syndrome Treatment Market Overview
  • 29.2. Africa Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Severe Acute Respiratory-Syndrome Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Severe Acute Respiratory-Syndrome Treatment Market Competitive Landscape
  • 30.2. Severe Acute Respiratory-Syndrome Treatment Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. F. Hoffmann-La Roche Ltd.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. AbbVie Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Merck And Co Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Novartis AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Severe Acute Respiratory-Syndrome Treatment Market Other Major And Innovative Companies

  • 31.1. Bristol Myers Squib company
  • 31.2. GlaxoSmithKline plc
  • 31.3. AstraZeneca plc
  • 31.4. Sanofi SA
  • 31.5. Eli Lilly And Company
  • 31.6. Gilead Sciences Inc.
  • 31.7. Amgen Inc.
  • 31.8. Johnson And Johnson Private Limited
  • 31.9. Moderna Inc.
  • 31.10. Regeneron Pharmaceuticals Inc.
  • 31.11. Hetero labs Ltd.
  • 31.12. Alexion Pharmaceuticals Inc.
  • 31.13. Cadila healthcare Ltd.
  • 31.14. Genentech Inc.
  • 31.15. Cipla Ltd.

32. Global Severe Acute Respiratory-Syndrome Treatment Market Competitive Benchmarking

33. Global Severe Acute Respiratory-Syndrome Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Severe Acute Respiratory-Syndrome Treatment Market

35. Severe Acute Respiratory-Syndrome Treatment Market Future Outlook and Potential Analysis

  • 35.1 Severe Acute Respiratory-Syndrome Treatment Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Severe Acute Respiratory-Syndrome Treatment Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Severe Acute Respiratory-Syndrome Treatment Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer